For the events upstream of EZH2 activation in bladder cancer models, it was shown that lncRNA TUG1 promoted cisplatin resistance via regulation of the CCND2 through EZH2-associated silencing of miR-194-5p [127]. This evidence concerns the gene EZH2 and urinary bladder cancer.